Redesign Science develops and applies a molecular dynamics-driven platform for in silico drug discovery against emerging drug target classes. We work in partnership with Biotech and Pharma to co-develop novel small molecule therapeutics.

Biotechnology

Redesign Science

David Rooklin

Janan Zhu

Scott Liu

Andrew Avorn

欢 刘

Sharon Blaettler

The leaders at Redesign Science have a history of working in research, both in academia and in the pharmaceutical industry. They have experience with a variety of diseases and research techniques, and they hold degrees in computational biology and biochemistry from NYU and Oberlin College, respectively.

Leadership Team

About

Team members